AURA
Aura Biosciences, Inc.
$7.60
-0.05
(-0.65%)
Mkt Cap
487.92M
Volume
269,510
52W Range
4.73-9.535
Sector
Healthcare
Beta
0.37
EPS (TTM)
-1.77
P/E Ratio
-3.10
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (106.19M) | (86.92M) | (76.41M) | (58.76M) | (35.25M) | (22.21M) | (24.20M) |
| EPS | -1.76 | -1.75 | -1.93 | -1.96 | -1.58 | -1.03 | -0.01 |
| Free Cash Flow | (85.19M) | (81.06M) | (64.56M) | (55.70M) | (34.53M) | (25.09M) | (22.89M) |
| FCF / Share | -1.41 | -1.63 | -1.63 | -1.86 | -1.18 | -0.86 | -0.01 |
| Operating CF | (84.74M) | (79.81M) | (63.85M) | (54.60M) | (32.41M) | (24.32M) | (20.67M) |
| Total Assets | 169.43M | 182.50M | 255.07M | 223.94M | 160.03M | 22.10M | 37.05M |
| Total Debt | 17.38M | 18.77M | 19.56M | 20.86M | 975,000 | 15,000 | 49,000 |
| Cash & Equiv | 59.52M | 31.69M | 41.06M | 121.58M | 149.06M | 17.39M | 32.47M |
| Book Value | 136.91M | 151.97M | 225.85M | 195.58M | 152.31M | 19.36M | 30.76M |
| Return on Equity | -0.78 | -0.57 | -0.34 | -0.30 | -0.23 | -1.15 | -0.79 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (33.69M) | (25.56M) | (26.13M) | (27.02M) | (27.48M) | (25.83M) | (21.04M) | (20.34M) | (19.71M) | (22.13M) | (18.51M) | (18.30M) |
| EPS | -0.50 | -0.40 | -0.40 | -0.47 | -0.55 | -0.52 | -0.42 | -0.41 | -0.40 | -0.50 | -0.48 | -0.48 |
| Free Cash Flow | (30.00M) | (20.64M) | (20.19M) | (20.81M) | (23.54M) | (24.25M) | (15.61M) | (16.65M) | (24.54M) | (17.70M) | (15.49M) | (14.84M) |
| FCF / Share | -0.44 | -0.34 | -0.31 | -0.36 | -0.47 | -0.49 | -0.31 | -0.34 | -0.50 | -0.40 | -0.41 | -0.39 |
| Operating CF | (29.89M) | (20.47M) | (20.14M) | (20.77M) | (23.36M) | (23.95M) | (15.27M) | (16.13M) | (24.45M) | (17.39M) | (15.40M) | (14.64M) |
| Total Assets | 137.68M | 169.43M | 190.02M | 204.40M | 155.40M | 182.50M | 205.34M | 218.28M | 235.03M | 255.07M | 179.77M | 192.74M |
| Total Debt | 16.99M | 17.38M | 17.75M | 18.11M | 18.44M | 18.77M | 19.08M | 19.03M | 19.32M | 19.56M | 20.19M | 20.41M |
| Cash & Equiv | 84.79M | 59.52M | 47.55M | 107.37M | 38.23M | 31.69M | 25.41M | 30.07M | 26.28M | 41.06M | 55.58M | 47.73M |
| Book Value | 107.25M | 136.91M | 156.67M | 174.63M | 127.97M | 151.97M | 174.67M | 191.45M | 208.78M | 225.85M | 151.72M | 166.44M |
| Return on Equity | -0.31 | -0.19 | -0.17 | -0.15 | -0.21 | -0.17 | -0.12 | -0.11 | -0.09 | -0.10 | -0.12 | -0.11 |
AURA News
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
AMG Reports Better than Expected First Quarter 2026 Results
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion